EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Co-expression of IL-15 and CCL21 strengthens CAR-NK cells to eliminate tumors in concert with T cells and equips them with PI3K/AKT/mTOR signal signature

Xindi Wang, Wenjing Luo, Zhaozhao Chen, Chenggong Li, Jie Zhou, Zhongpei Huang, Lu Tang, Jianghua Wu, Zhuolin Wu, Yingying Li, Yinqiang Zhang, Yun Kang und 6 weitere

Journal for ImmunoTherapy of Cancer · 2025-06 · 13 (6) · e010822

DOI: 10.1136/jitc-2024-010822 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 15.06.2025. Verfasst von Xindi Wang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Hauptthemen laut MEDLINE: Interleukin-15, Killer Cells, Natural, Proto-Oncogene Proteins c-akt, TOR Serine-Threonine Kinases. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chimeric antigen receptor (CAR)-natural killer (NK) cell therapy has demonstrated safety and feasibility in clinical settings; however, limited efficacy due to intrinsic dysfunction and extrinsic suppression remains an unresolved issue. T cells provide multifaceted support to NK cell-mediated responses. Here, we aimed to design a novel CD19-targeted CAR-NK, engineered with secreted interleukin-15 and C-C motif chemokine ligand 21 (ie, 15×21 CAR-NK), capable of recruiting and cooperating with T cells.

Methods

We characterized 15×21 CAR-NK cells by performing experiments in vitro and in mouse models, and conducting RNA sequencing.

Results

15×21 CAR-NK cells exhibit strong capabilities in cytotoxicity, cytokine production, effector molecule expression, and T-cell recruitment in vitro. Cooperation with T cells promoted efficient tumor-cell elimination, alleviated mutual exhaustion phenotypes, and enhanced the expression of effector molecules/receptors. The recruitment and cooperative effects also result in effective tumor control in mouse models. In addition, 15×21 CAR-NK cells strongly enrich the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway - a key intracellular signaling cascade that is associated with enhanced downstream pro-survival signaling, anti-apoptotic ability, mitochondrial function, and cytotoxicity.

Conclusions

Our study highlights the intrinsic advantages and extrinsic T-cell cooperative benefits of 15×21 CAR-NK cells, providing a promising strategy for NK-cell-based immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-15Killer Cells, NaturalProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesPhosphatidylinositol 3-KinasesChemokine CCL21Receptors, Chimeric AntigenImmunotherapy, AdoptiveT-LymphocytesAnimalsMiceHumansSignal TransductionCell Line, Tumor

Stichwörter der Autor:innen

Chimeric antigen receptor - CARLymphomaMitochondriaNatural killer - NK

Substanzen

Interleukin-15Proto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesPhosphatidylinositol 3-KinasesChemokine CCL21Receptors, Chimeric AntigenIL15 protein, human

Autor:innen und Institutionen

  • Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, Hubei, China.
  • Key Laboratory of Biological Targeted Therapy (Huazhong University of Science and Technology), Ministry of Education, Wuhan, Hubei, China.
  • Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China hmei@hust.edu.cn dr_huyu@126.com.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wang, X., Luo, W., Chen, Z., Li, C., Zhou, J., Huang, Z., Tang, L., Wu, J., Wu, Z., Li, Y., Zhang, Y., Kang, Y., Liu, Q., Xu, J., Xiong, W., Deng, J., Mei, H., & Hu, Y. (2025). Co-expression of IL-15 and CCL21 strengthens CAR-NK cells to eliminate tumors in concert with T cells and equips them with PI3K/AKT/mTOR signal signature. Journal for ImmunoTherapy of Cancer, 13(6), e010822. https://doi.org/10.1136/jitc-2024-010822

Vancouver

Wang X, Luo W, Chen Z, Li C, Zhou J, Huang Z, et al. Co-expression of IL-15 and CCL21 strengthens CAR-NK cells to eliminate tumors in concert with T cells and equips them with PI3K/AKT/mTOR signal signature. Journal for ImmunoTherapy of Cancer. 2025;13(6):e010822. doi:10.1136/jitc-2024-010822

BibTeX
@article{Wang2025,
  author = {Wang, Xindi and Luo, Wenjing and Chen, Zhaozhao and Li, Chenggong and Zhou, Jie and Huang, Zhongpei and Tang, Lu and Wu, Jianghua and Wu, Zhuolin and Li, Yingying and Zhang, Yinqiang and Kang, Yun and Liu, Qiaolin and Xu, Jia and Xiong, Wei and Deng, Jun and Mei, Heng and Hu, Yu},
  title = {Co-expression of IL-15 and CCL21 strengthens CAR-NK cells to eliminate tumors in concert with T cells and equips them with PI3K/AKT/mTOR signal signature},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  volume = {13},
  number = {6},
  pages = {e010822},
  doi = {10.1136/jitc-2024-010822}
}
Kostenlos starten →